MAPT and Alzheimer disease: This is of interest to tau-targeting clinical trials given that it increases longitudinally as the AD continuum advances from tau pathology onset, with high correlation to tau PET and cognitive decline, indicating it as a tau tangle-specific biomarker [85, 86].